167 related articles for article (PubMed ID: 38607373)
1. Exploratory mass cytometry analysis reveals immunophenotypes of cancer treatment-related pneumonitis.
Yanagihara T; Hata K; Matsubara K; Kunimura K; Suzuki K; Tsubouchi K; Ikegame S; Baba Y; Fukui Y; Okamoto I
Elife; 2024 Apr; 12():. PubMed ID: 38607373
[TBL] [Abstract][Full Text] [Related]
2. Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease.
Suzuki K; Yanagihara T; Matsumoto K; Kusaba H; Yamauchi T; Ikematsu Y; Tanaka K; Otsubo K; Inoue H; Yoneshima Y; Iwama E; Arimura-Omori M; Harada E; Hamada N; Okamoto I; Nakanishi Y
Int Immunol; 2020 Jul; 32(8):547-557. PubMed ID: 32253426
[TBL] [Abstract][Full Text] [Related]
3. Mass cytometry identifies characteristic immune cell subsets in bronchoalveolar lavage fluid from interstitial lung diseases.
Hata K; Yanagihara T; Matsubara K; Kunimura K; Suzuki K; Tsubouchi K; Eto D; Ando H; Uehara M; Ikegame S; Baba Y; Fukui Y; Okamoto I
Front Immunol; 2023; 14():1145814. PubMed ID: 36949950
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer Patients with Interstitial Lung Disease: Significance of Radiological Pleuroparenchymal Fibroelastosis.
Osaki M; Arai T; Sumikawa H; Takimoto T; Takeuchi N; Tamiya A; Okishio K; Inoue Y
Oncology; 2023; 101(5):303-312. PubMed ID: 36689929
[TBL] [Abstract][Full Text] [Related]
5. Single-cell transcriptomics identifies pathogenic T-helper 17.1 cells and pro-inflammatory monocytes in immune checkpoint inhibitor-related pneumonitis.
Franken A; Van Mol P; Vanmassenhove S; Donders E; Schepers R; Van Brussel T; Dooms C; Yserbyt J; De Crem N; Testelmans D; De Wever W; Nackaerts K; Vansteenkiste J; Vos R; Humblet-Baron S; Lambrechts D; Wauters E
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171010
[TBL] [Abstract][Full Text] [Related]
6. T cell immunity in interstitial lung disease with non-small cell lung cancer patients.
Isono T; Iwahori K; Yanagawa M; Yamamoto Y; Tone M; Haruna M; Hirata M; Fukui E; Kimura T; Kanou T; Ose N; Funaki S; Takeda Y; Morii E; Kumanogoh A; Shintani Y; Wada H
Lung Cancer; 2023 Aug; 182():107278. PubMed ID: 37321075
[TBL] [Abstract][Full Text] [Related]
7. High proportion of gamma-delta T cell receptor positive T cells in bronchoalveolar lavage and peripheral blood of HIV-infected patients with Pneumocystis carinii pneumonias.
Kägi MK; Fierz W; Grob PJ; Russi EW
Respiration; 1993; 60(3):170-7. PubMed ID: 7692576
[TBL] [Abstract][Full Text] [Related]
8. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
Yamagata A; Yokoyama T; Fukuda Y; Ishida T
Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy-related pneumonitis and the synergic impact of thoracic radiation and preexisting interstitial lung disease.
Azhar M; Abrencillo R; Gandhi S; Altan M; Sheshadri A
Curr Opin Pulm Med; 2023 Jul; 29(4):248-255. PubMed ID: 37170920
[TBL] [Abstract][Full Text] [Related]
10. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary Complications.
Kim ST; Sheshadri A; Shannon V; Kontoyiannis DP; Kantarjian H; Garcia-Manero G; Ravandi F; Im JS; Boddu P; Bashoura L; Balachandran DD; Evans SE; Faiz S; Ruiz Vazquez W; Divenko M; Mathur R; Tippen SP; Gumbs C; Neelapu SS; Naing A; Wang L; Diab A; Futreal A; Nurieva R; Daver N
Front Immunol; 2020; 11():590494. PubMed ID: 33552049
[TBL] [Abstract][Full Text] [Related]
11. Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study.
Kowalski B; Valaperti A; Bezel P; Steiner UC; Scholtze D; Wieser S; Vonow-Eisenring M; Widmer A; Kohler M; Franzen D
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1711-1720. PubMed ID: 34347128
[TBL] [Abstract][Full Text] [Related]
12. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
[TBL] [Abstract][Full Text] [Related]
13. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
[TBL] [Abstract][Full Text] [Related]
14. Characterization of immunomodulatory factors and cells in bronchoalveolar lavage fluid for immune checkpoint inhibitor-related pneumonitis.
Wang PM; Zhang ZW; Zhang S; Xing Q; Zhao ZY; Lin QH; Shen LH; Xia ZL; Li FF; Zhu B
J Cancer Res Clin Oncol; 2023 Aug; 149(10):8019-8026. PubMed ID: 36944820
[TBL] [Abstract][Full Text] [Related]
15. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody.
Shibaki R; Murakami S; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Kusumoto M; Yamamoto N; Ohe Y
Cancer Immunol Immunother; 2020 Jan; 69(1):15-22. PubMed ID: 31745589
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of PD-1 T lymphocytes in bronchoalveolar lavage in lung cancer compared to benign lung diseases.
Hammer B; Bal C; Gysan M; Zehetmayer S; Geleff S; Zech A; Kramer M; Ayazseven S; Idzko M; Mosleh B; Hoda MA; Gompelmann D
Clin Exp Med; 2023 Dec; 23(8):5177-5182. PubMed ID: 37535195
[TBL] [Abstract][Full Text] [Related]
17. Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
Petranovic M; McDermott S; Mercaldo S; Little BP; Graur A; Huang K; Fintelmann FJ; Digumarthy SR; Gainor JF
Clin Lung Cancer; 2023 Dec; 24(8):682-688.e5. PubMed ID: 37758549
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Concomitant Usage of Analgesics on Immune Checkpoint Inhibitor-related Interstitial Lung Disease.
Manabe T; Iwayama K; Chuma M; Tasaki Y; Matsumoto S
In Vivo; 2023; 37(3):1260-1265. PubMed ID: 37103090
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
